JP2015501329A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501329A5
JP2015501329A5 JP2014539463A JP2014539463A JP2015501329A5 JP 2015501329 A5 JP2015501329 A5 JP 2015501329A5 JP 2014539463 A JP2014539463 A JP 2014539463A JP 2014539463 A JP2014539463 A JP 2014539463A JP 2015501329 A5 JP2015501329 A5 JP 2015501329A5
Authority
JP
Japan
Prior art keywords
conjugate
antigen
amino acid
acid sequence
spr0096
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539463A
Other languages
English (en)
Japanese (ja)
Other versions
JP6170932B2 (ja
JP2015501329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/056240 external-priority patent/WO2013068949A1/en
Publication of JP2015501329A publication Critical patent/JP2015501329A/ja
Publication of JP2015501329A5 publication Critical patent/JP2015501329A5/ja
Application granted granted Critical
Publication of JP6170932B2 publication Critical patent/JP6170932B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539463A 2011-11-07 2012-11-07 spr0096抗原およびspr2021抗原を含むキャリア分子 Expired - Fee Related JP6170932B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556456P 2011-11-07 2011-11-07
US61/556,456 2011-11-07
US201161566407P 2011-12-02 2011-12-02
US61/566,407 2011-12-02
PCT/IB2012/056240 WO2013068949A1 (en) 2011-11-07 2012-11-07 Carrier molecule comprising a spr0096 and a spr2021 antigen

Publications (3)

Publication Number Publication Date
JP2015501329A JP2015501329A (ja) 2015-01-15
JP2015501329A5 true JP2015501329A5 (enExample) 2015-12-24
JP6170932B2 JP6170932B2 (ja) 2017-07-26

Family

ID=47216379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539463A Expired - Fee Related JP6170932B2 (ja) 2011-11-07 2012-11-07 spr0096抗原およびspr2021抗原を含むキャリア分子

Country Status (9)

Country Link
US (1) US9493517B2 (enExample)
EP (1) EP2776069A1 (enExample)
JP (1) JP6170932B2 (enExample)
CN (1) CN104080479B (enExample)
AU (1) AU2012335208B2 (enExample)
CA (1) CA2854934A1 (enExample)
MX (1) MX354924B (enExample)
RU (1) RU2636350C2 (enExample)
WO (1) WO2013068949A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543907A (ja) * 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2481040T3 (es) * 2008-12-09 2014-07-29 Coley Pharmaceutical Group, Inc. Oligonucleótidos inmunoestimulantes
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
PT3506935T (pt) 2016-09-02 2024-04-01 Sanofi Pasteur Inc Vacina contra neisseria meningitidis
WO2018126229A2 (en) * 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
GB201705184D0 (en) 2017-03-31 2017-05-17 Sharman H D Ltd Monitoring apparatus for guttering systems
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
WO2020010016A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
ES2989087T3 (es) * 2018-07-04 2024-11-25 Vaxcyte Inc Mejoras en conjugados inmunogénicos
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
HU222111B1 (hu) 1991-03-01 2003-04-28 Minnesota Mining And Manufacturing Co. 1H-imidazo[4,5-c]kinolin-származékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PL175595B1 (pl) 1992-08-31 1999-01-29 North American Vaccine Inc Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
US5508191A (en) 1993-07-05 1996-04-16 Takeda Chemical Industries, Ltd. Mutant strains of agrobacterium for producing β-1,3-glucan
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔4,5−c〕ピリジン−4−アミン
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
AU695720B2 (en) 1995-06-07 1998-08-20 Smithkline Beecham Biologicals (Sa) Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
WO1999027105A2 (en) 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DK1221955T3 (da) 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
DK1248647T3 (da) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
EP2166019A3 (en) 2000-07-03 2010-06-09 Novartis Vaccines and Diagnostics S.r.l. Immunisation against Chlamydia Pneumoniae
WO2002018383A2 (en) 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
AU2002309706A1 (en) * 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
KR100718371B1 (ko) 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 3-β-D-리보푸라노실티아졸로[4,5-d]피리디민누클레오시드 및 이의 용도
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DK1490409T3 (da) 2002-03-26 2009-03-23 Novartis Vaccines & Diagnostic Modificerede saccharider med forbedret stabilitet i vand
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
JP2005531599A (ja) 2002-05-29 2005-10-20 スリーエム イノベイティブ プロパティズ カンパニー イミダゾ[4,5−c]ピリジン−4−アミンのための方法
US7273852B2 (en) 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US6932971B2 (en) * 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
AU2003260102A1 (en) 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
CA2498847C (en) 2002-09-13 2014-10-28 Chiron Corporation Group b streptococcus vaccine
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
CN102174534A (zh) 2003-04-15 2011-09-07 英特塞尔股份公司 肺炎链球菌抗原
ES2317043T3 (es) 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
SI1742659T1 (sl) 2004-04-05 2013-07-31 Zoetis P Llc Mikrofluidizirane emulzije olja v vodi in sestavki cepiv
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
CN101107010A (zh) 2004-11-01 2008-01-16 布里格海姆妇女医院公司 经修饰的链球菌多糖及其用途
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
JP2008543907A (ja) 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN100462102C (zh) * 2007-02-07 2009-02-18 重庆智仁生物技术有限公司 脑膜炎球菌多价联合疫苗
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2773637A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー E.coliキャリアタンパク質に結合体化した多糖免疫原

Similar Documents

Publication Publication Date Title
JP2015501329A5 (enExample)
RU2014123021A (ru) Молекула, содержащая spr0096 и spr2021
ES2251124T3 (es) Vacuna que comprende un antigeno de streptococcus pneumoniae adyuvado por un oligonucleotido cpg.
JP2017523985A5 (enExample)
JP2013079285A5 (enExample)
AR084158A1 (es) Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
AR107018A2 (es) Composición de conjugado polisacárido neomocóccico multivalente-proteína
IL260135A (en) Preparations and methods of neisseria meningitidis
JP2014515036A5 (enExample)
JP2010515718A5 (enExample)
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
JP2011523412A5 (enExample)
CY1109582T1 (el) Συνδυασμενα μηνιγγοκοκκινα συζευγματα με κοινη πρωτεϊνη φορεα
ATE383872T1 (de) Ein immunostimulierendes nukleotid und ein tocol enthaltende zusammensetzung
WO2004050705A3 (en) Complexes of receptors
EA201290690A1 (ru) Иммуногенная композиция, содержащая полисахариды s.pneumoniae, конъюгированные с белками-носителями
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
JP2009535021A5 (enExample)
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
JP2015505309A5 (enExample)
JP2017503014A5 (enExample)
JP2020523384A5 (enExample)
HK1207305A1 (en) Stabilized formulations containing anti-dll4 antibodies
CN107223133A (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
JP2011504736A5 (enExample)